This October the U.S. and Mexico agreed on a new bilateral security program, but "unless the United States and Mexico pursue domestic structural reforms ... both nations risk backsliding to the failures of the drug wars," writes MGA student and Drug Policy guest contributor Sidney Phillips.
The authors explore the costs and benefits of a legalization program, contending that to realize the full benefits of comprehensive immigration reform and deter future unauthorized immigration, a broad and inclusive legalization program is needed.
Paris and Washington are past the immediate AUKUS crisis, but two major, related issues will remain high on Biden’s foreign policy agenda for the balance of his term, writes fellow Joe Barnes: China’s military expansion in the Pacific and the EU’s role in great power politics.
Read more at the Baker Institute Blog.
China’s request for membership in the Comprehensive and Progressive Trans-Pacific Partnership, from which the U.S. withdrew in 2017, creates diplomatic challenges for the U.S. as well as foreign policy hurdles for current CPTPP members, the authors write.
David A. Gantz, Jorge Huerta-GoldmanOctober 5, 2021
In the push for decarbonization, "turquoise" hydrogen offers a unique, commercially viable technology that reduces CO2 emissions, argue Rachel A. Meidl and Kenneth B. Medlock III.
Rachel A. Meidl, Kenneth B. Medlock IIISeptember 23, 2021
We are in the midst of one of the largest and most rapid humanitarian evacuation missions in American history. Where will fleeing Afghans go? Middle East fellow Kelsey Norman describes an inadequate U.S. response and recommends ways forward.
The leader of Argentina's most influential oil and natural gas workers union is handing off the reins to a more combative successor. The government and energy firms active in the Vaca Muerta are concerned. Read more in Mark Jones' Forbes post on the Baker Institute Blog.
In this report, the authors outline the U.S. federal budget process for scientific R&D, discuss trends in federal R&D funding and provide an outlook for federal scientific R&D funding during the Biden administration.